echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Scientists have discovered a highly effective antibody with 4-6 months of protection against SARS-CoV-2

    Scientists have discovered a highly effective antibody with 4-6 months of protection against SARS-CoV-2

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The newly identified antibody was isolated from the lymphocytes of COVID-19 patients who participated in the immunization coronavirus research conducted by CHUV's Immunization and Allergy Service Center
    .
    This antibody is one of the most effective antibodies against SARS-CoV-2 identified so far

    .
    The structural characteristics of the antibody indicate that it binds to a region that is not subject to mutation by the spike protein

    .
    Through this close interaction, the antibody prevents the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor for viruses to enter and infect lung cells

    .
    This means that the antibody prevents the virus replication process, allowing the patient's immune system to clear SARS-CoV-2 from the body

    .
    This protective mechanism was confirmed by in vivo experiments on hamsters; specimens injected with antibodies can prevent infection even after receiving high infectious doses

    .

    In addition to its antiviral properties, this new antibody is also designed to have a lasting effect on humans
    .
    A typical unchanged antibody can provide protection for up to 3-4 weeks

    .
    But this new one can protect the patient for 4-6 months

    .
    This makes it an interesting preventive treatment option, as there is no immune response to non-vaccinated high-risk groups or vaccinated people

    .
    Immunocompromised patients, organ transplant patients and certain cancer patients receive 2 to 3 antibody injections per year to prevent SARS-CoV-2

    .

    Currently, CHUV and EPFL plan to cooperate with a start-up company to carry out clinical development and production of this antibody-containing drug through cooperation and intellectual property agreements
    .
    Clinical trials of the drug will begin at the end of 2022

    .

    Treatment or prophylaxy

    This research was conducted by CHUV's immunology and allergy services led by Professors Giuseppe Pantaleo and Craig Fenwick, and EPFL's Virology and Genetics Laboratory led by Professor Didier Trono and Dr.
    Priscilla Turelli

    .
    Thanks to the support of the Swiss Vaccine Institute for many years, the research team was able to respond to the pandemic and discovered this neutralizing antibody so quickly

    .
    The CHUV department where Professor Pantaleo works is also supported by the Corona Accelerated R&D in Europe (CARE) project, which is part of the Innovative Medicine Initiative (IMI), a public-private organization that aims to solve bottlenecks in the European drug discovery and development process Partnership

    .

    The discovery of this new antibody marks an important step forward in the fight against COVID-19
    .
    It opens the door for improving the treatment of serious diseases and strengthening preventive measures, especially for patients with weakened immune systems

    .
    However, this antibody is not intended to replace the COVID-19 vaccine, which is still the most effective way to prevent infection

    .

    references

    Craig Fenwick, Priscilla Turelli, Laurent Perez, Céline Pellaton, Line Esteves-Leuenberger, Alex Farina, Jérémy Campos, Erica Lana, Flurin Fiscalini, Charlène Raclot, Florence Pojer, Kelvin Lau, Davide Demurtas, Marc Descatoire, Victor S.
    Joo Foglierini, Alessandra Noto, Rana Abdelnabi, Caroline S.
    Foo, Laura Vangeel, Johan Neyts, Wenjuan Du, Berend-Jan Bosch, Geertruida Veldman, Pieter Leyssen, Volker Thiel, Roger LeGrand, Yves Lévy, Didier Trono, Giuseppe Pantaleo, one kind Highly effective antibodies against SARS-CoV-2 mutations, cell report, 2021

    https://doi.
    org/10.
    1016/j.
    celrep.
    2021.
    109814


    Magazine

    Cell report

    DOI

    10.
    1016/j.
    celrep.
    2021.
    109814

    Methodological research

    Experimental Study

    Subject of research

    animal

    Article title

    A highly effective antibody against SARS-CoV-2 mutation

    Article publication date

    12-October-2021

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.